Combination immunotherapy for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with extensive-stage small cell lung cancer that has progressed despite prior treatment with immunotherapy (anti-PD-1/PD-L1 drugs).
- You have at least one tumor that can be measured on scans and has not been previously treated with radiation (or has clearly grown after radiation).
- You are able to take care of yourself (ECOG performance status 0 or 1).
- Your major organs (bone marrow, liver, kidneys, heart) must be functioning adequately, as determined by blood tests and heart tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a cholesterol-lowering drug to a combination of two other drugs can help people with advanced non-small cell lung cancer whose cancer has grown after prior immunotherapy. It aims to find a new treatment option for those who have run out of standard options.
This trial looks at whether adding a targeted therapy called anlotinib to immunotherapy maintenance can help people with extensive-stage small cell lung cancer who have already completed 4-6 cycles of standard chemoimmunotherapy without the cancer getting worse.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
This trial tests a combination of two drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after one prior treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
Hear when a new Resistance to Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.